Henry Git ری ٹویٹ کیا

Localised prostate cancer just changed. Again.
ESMO 2026 brings clarity on who to observe, who to escalate, and which trials actually matter 👇
🧠 Diagnosis
MRI before biopsy is standard
High-resolution US is a valid alternative (RCT n=678)
🧭 Low risk
Active surveillance is safe
ProtecT 15-yr data shows similar survival vs RP/RT
☢️ Radiotherapy
Shorter is better
CHHiP ➜ moderate hypofractionation
HYPO-RT-PC ➜ ultra-hypofractionation
PACE-B ➜ SBRT works in selected IR disease
📈 High risk
RT + long-term ADT saves lives
SPCG-7 | NCIC/MRC
Dose escalation improves OS (GETUG-AFU 18)
🚨 Very high-risk / cN1
RT + ADT + abiraterone is the new benchmark
STAMPEDE delivers MFS + OS benefit
🔁 Biochemical recurrence
Avoid routine adjuvant RT
Early salvage RT preferred
RADICALS-RT | RAVES | GETUG-AFU 17
High-risk BCR? Intensify
EMBARK supports enzalutamide + ADT
🧠 Bottom line
Risk-adapted care > overtreatment
Imaging-driven decisions
Escalate only when trials prove benefit
📖 Full paper in comment ⬇️
#OncoTwitter #MedTwitter #ProstateCancer #GUOncology
@OncoAlert @myesmo @esmo_open @asco @OncBrothers

English
















































